Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
110 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Klebsiella pneumoniae Infections - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Klebsiella pneumoniae Infections - Pipeline Review, H1 2016', provides an overview of the Klebsiella pneumoniae Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections - The report reviews pipeline therapeutics for Klebsiella pneumoniae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Klebsiella pneumoniae Infections therapeutics and enlists all their major and minor projects - The report assesses Klebsiella pneumoniae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Klebsiella pneumoniae Infections - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Klebsiella pneumoniae Infections Overview 11 Therapeutics Development 12 Pipeline Products for Klebsiella pneumoniae Infections - Overview 12 Pipeline Products for Klebsiella pneumoniae Infections - Comparative Analysis 13 Klebsiella pneumoniae Infections - Therapeutics under Development by Companies 14 Klebsiella pneumoniae Infections - Therapeutics under Investigation by Universities/Institutes 16 Klebsiella pneumoniae Infections - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Klebsiella pneumoniae Infections - Products under Development by Companies 20 Klebsiella pneumoniae Infections - Products under Investigation by Universities/Institutes 22 Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development 23 Arsanis Biosciences GmbH 23 Cellceutix Corporation 24 Debiopharm International SA 25 Evaxion Biotech ApS 26 F. Hoffmann-La Roche Ltd. 27 FOB Synthesis, Inc. 28 Melinta Therapeutics, Inc 29 Merck & Co., Inc. 30 MicuRx Pharmaceuticals, Inc. 31 Nosopharm SAS 32 Pfizer Inc. 33 Phico Therapeutics Limited 34 Procarta Biosystems Limited 35 Sarepta Therapeutics, Inc. 36 Shionogi & Co., Ltd. 37 Soligenix, Inc. 38 Sumitomo Dainippon Pharma Co., Ltd. 39 Syntiron LLC 40 Tetraphase Pharmaceuticals Inc. 41 Theraclone Sciences, Inc. 42 Varinel, Inc. 43 Klebsiella pneumoniae Infections - Therapeutics Assessment 44 Assessment by Monotherapy Products 44 Assessment by Target 45 Assessment by Mechanism of Action 47 Assessment by Route of Administration 49 Assessment by Molecule Type 51 Drug Profiles 53 Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 ASN-300 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 CB-027 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 CB-618 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 CC-1807 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 CTIX-1278 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Debio-1454 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 dusquetide - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 FSI-1671 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 FSI-1686 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 GN snare - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 IBN-1 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Klebsiella pneumoniae vaccine - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Klebsiella pneumoniae vaccine - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Monoclonal Antibody for Klebsiella Pneumoniae Infections - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 MRX-V - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 NOSO-95179 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Onc-72 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 PMX-100 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 PMX-1091 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 PMX-1142 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 PMX-229 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 PMX-633 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 pneumonia vaccine - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 pneumonia vaccine - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 PT-4 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 RX-05 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 RXP-792 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 RXP-873 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 S-649266 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 SM-295291 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 SM-369926 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Small Molecules for Bacterial Infections - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Small Molecules for Klebsiella pneumoniae Infections - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Synthetic Peptide for Klebsiella Pneumoniae Infections - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 TP-076 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 TP-6076 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 VAR-10100 - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Klebsiella pneumoniae Infections - Recent Pipeline Updates 99 Klebsiella pneumoniae Infections - Dormant Projects 106 Klebsiella pneumoniae Infections - Discontinued Products 107 Klebsiella pneumoniae Infections - Product Development Milestones 108 Featured News & Press Releases 108 Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae Towards Clinical Trials 108 Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CB-027 At ICAAC 2012 108 Appendix 109 Methodology 109 Coverage 109 Secondary Research 109 Primary Research 109 Expert Panel Validation 109 Contact Us 109 Disclaimer 110
List of Tables
Number of Products under Development for Klebsiella pneumoniae Infections, H1 2016 12 Number of Products under Development for Klebsiella pneumoniae Infections - Comparative Analysis, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Number of Products under Development by Companies, H1 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Comparative Analysis by Late Stage Development, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Development, H1 2016 19 Products under Development by Companies, H1 2016 20 Products under Development by Companies, H1 2016 (Contd..1) 21 Products under Investigation by Universities/Institutes, H1 2016 22 Klebsiella pneumoniae Infections - Pipeline by Arsanis Biosciences GmbH, H1 2016 23 Klebsiella pneumoniae Infections - Pipeline by Cellceutix Corporation, H1 2016 24 Klebsiella pneumoniae Infections - Pipeline by Debiopharm International SA , H1 2016 25 Klebsiella pneumoniae Infections - Pipeline by Evaxion Biotech ApS, H1 2016 26 Klebsiella pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 27 Klebsiella pneumoniae Infections - Pipeline by FOB Synthesis, Inc., H1 2016 28 Klebsiella pneumoniae Infections - Pipeline by Melinta Therapeutics, Inc, H1 2016 29 Klebsiella pneumoniae Infections - Pipeline by Merck & Co., Inc., H1 2016 30 Klebsiella pneumoniae Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2016 31 Klebsiella pneumoniae Infections - Pipeline by Nosopharm SAS, H1 2016 32 Klebsiella pneumoniae Infections - Pipeline by Pfizer Inc., H1 2016 33 Klebsiella pneumoniae Infections - Pipeline by Phico Therapeutics Limited, H1 2016 34 Klebsiella pneumoniae Infections - Pipeline by Procarta Biosystems Limited, H1 2016 35 Klebsiella pneumoniae Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2016 36 Klebsiella pneumoniae Infections - Pipeline by Shionogi & Co., Ltd., H1 2016 37 Klebsiella pneumoniae Infections - Pipeline by Soligenix, Inc., H1 2016 38 Klebsiella pneumoniae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 39 Klebsiella pneumoniae Infections - Pipeline by Syntiron LLC, H1 2016 40 Klebsiella pneumoniae Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 41 Klebsiella pneumoniae Infections - Pipeline by Theraclone Sciences, Inc., H1 2016 42 Klebsiella pneumoniae Infections - Pipeline by Varinel, Inc., H1 2016 43 Assessment by Monotherapy Products, H1 2016 44 Number of Products by Stage and Target, H1 2016 46 Number of Products by Stage and Mechanism of Action, H1 2016 48 Number of Products by Stage and Route of Administration, H1 2016 50 Number of Products by Stage and Molecule Type, H1 2016 52 Klebsiella pneumoniae Infections Therapeutics - Recent Pipeline Updates, H1 2016 99 Klebsiella pneumoniae Infections - Dormant Projects, H1 2016 106 Klebsiella pneumoniae Infections - Discontinued Products, H1 2016 107
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
